 I would agree completely with Bill. I mean, I think we need to make it easier for the companies and the investors to see a path forward in transplant. Right now, the problem is every trial that's done takes a decade. It costs a lot of money, as Bill mentioned. And at the end, what I'm allowed to say is I have a new therapy that's no worse than the old therapy.